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The Expression and Regulation of Adrenomedullin
in the Human Endometrium: A Candidate for
Endometrial Repair
Jacqueline A. Maybin,* Sharon Battersby,* Nikhil Hirani, Leonid L. Nikitenko,
Hilary O. D. Critchley, and Henry N. Jabbour
The University of Edinburgh’s Centre for Reproductive Biology (J.A.M., H.O.D.C.), The Medical Research
Council Human Reproductive Sciences Unit (S.B., H.J.), and The Medical Research Council Centre for
Inflammation Research (N.H.), The Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United
Kingdom; and Cancer Research United Kingdom Viral Oncology Group (L.L.N.), University College
London Cancer Institute, University College London, London WC1E 6BT, United Kingdom
After menstruation, the endometrium has a remarkable capacity for repair, but the factors in-
volved remain undefined. We hypothesize adrenomedullin (AM) plays a role in this process. Pre-
menstrually progesterone levels decline, stimulating prostaglandin (PG) synthesis, vasoconstric-
tion, and hypoxia. This study aimed to determine 1) AM expression throughout themenstrual (M)
cycle and 2) its regulation by PG and hypoxia. Human endometrial biopsies (n 51) were collected
withethical approval andconsent.AMmRNAexpressionwasexaminedbyquantitativeRT-PCRand
was found tobe selectively elevated inendometriumfromthemenstrual (M)phase (P0.001).AM
immunohistochemical staining was maximal in M and proliferative (P) endometrium. Culture of
secretory, but not P, explants with 100 nM PGF2 or hypoxia (0.5% O2) increased AM mRNA (P 
0.05). P explants were induced to increase AM expression using in vitro progesterone withdrawal
but required thepresenceof hypoxia (P 0.05). Short hairpin sequences against hypoxia-inducible
factor-1 (HIF-1) inhibitedAMhypoxic up-regulation but did not alter PGF2-induced expression.
The AM receptor was immunolocalized to endothelial cells in both lymphatic and blood vessels.
Conditionedmedium fromPGF2-treated cells increased endothelial cell proliferation and branch-
ing (P 0.05). This was abolished by AM receptor antagonists. In conclusion, AM is elevated at the
time of endometrial repair and induces both angiogenesis and lymphangiogenesis by stimulating
endothelial cell proliferation and tube formation. In the human endometrium, AM expression is
up-regulatedby twomechanisms: aHIF-1-mediatedhypoxic induction andaHIF-1-independent
PGF2 pathway. These physiological mechanisms may provide novel therapeutic targets for disor-
ders such as heavy menstrual bleeding. (Endocrinology 152: 2845–2856, 2011)
The human endometrium is cyclically subjected to in-flammation and tissue destruction during menstrua-
tion. Its capacity for scar-free repair is remarkable, but the
factors involved remain elusive. Delineation of this effi-
cient repair process may reveal novel therapeutic targets
for complaints such as heavy menstrual bleeding (HMB).
In addition, the physiological mechanisms of endometrial
repair may be applicable to tissues elsewhere in the body,
where inflammation can lead to pathogenic fibrosis and
scarring.
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Abbreviations: AM, Adrenomedullin; CCM, control conditioned medium; CD31, platelet
endothelial cell adhesionmolecule; CGRP, calcitonin gene-related peptide; CLR, calcitonin
receptor-like receptor; COX, cyclo-oxygenase; ES, early secretory; GE, glandular epithe-
lium;HDLEC,humandermal lymphatic endothelial cell;HIF, hypoxia-inducible factor;HMB,
heavymenstrual bleeding;HUVEC,humanumbilical vein endothelial cell; LS, late secretory;
M, menstrual; MPA, medroxyprogesterone acetate; MS, midsecretory; P, proliferative;
PCM, PGF2-treated conditioned medium; PG, prostaglandin; Q-RT-PCR, quantitative RT-
PCR; RAMP, receptor activity-modifying protein; SE, surface epithelium; shRNA, short
hairpin RNA; St, stromal compartment.
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Premenstrually, the endometrium is exposed to high
levels of progesterone, secreted from the corpus luteum. In
the absence of pregnancy, the corpus luteum regresses and
progesterone levels fall dramatically. It is well established
that this progesterone withdrawal initiates a cascade of
inflammatorymediators thatculminates intissuedestruction
and menstruation (1). Hormone levels remain low during
menstruation, until the proliferative (P) phase commences
and estrogen levels rise. Traditionally, endometrial repair
was thought tobe regulatedbyestrogen,but recent studies in
amousemodel have suggested it is an estrogen-independent
event (2).Therefore,wehypothesizedthatpremenstrualpro-
gesterone withdrawal simultaneously triggers endometrial
breakdown and initiates repair.
Progesterone withdrawal is known to up-regulate cyclo-
oxygenase (COX)-2, the enzyme stimulating prostaglandin
(PG) synthesis (3, 4). PGF2 is a potent vasoconstrictor and,
alongside other vasoactive factors, causes constriction of en-
dometrial spiral arterioles. This leads to an episode of local,
transient hypoxia in the uppermost endometrial zones dur-
ingmenstruation.This hypoxic episodewas first observed in
classic experiments in the rhesus monkey (5) and was re-
cently detected in themousemodel of menstruation (6). Use
of pimonidazole, amarker of oxygen levels less than 10mm
Hg, demonstrated intense hypoxia in the luminal portion of
theendometriumond2ofthecycle,withnegligibledetection
by d 5. In addition, markers of tissue hypoxia [carbonic an-
hydrase IX and hypoxia-inducible factor (HIF)-1] have
been detected immunohistochemically in the human endo-
metrium during menstruation (7, 8).
Adrenomedullin (AM) is a pluripotent peptide that be-
longs to the calcitonin gene peptide superfamily. It has a
wide range of biological actions, including vasodilation
(9–11), induction of angiogenesis (12–14), cell growth
(15), and inhibition of apoptosis (16, 17). AM has an
attractive but previously undefined role in human endo-
metrial repair. AM acts through a G protein-coupled re-
ceptor, the calcitonin receptor-like receptor (CLR). Re-
ceptor activity-modifyingproteins (RAMP)associatewith
CLR to determine its ligand binding specificity (18). CLR
association with RAMP2 or RAMP3 promotes AM bind-
ing, whereas heterodimerization with RAMP1 promotes
calcitonin gene-related peptide (CGRP) binding. Hypoxia
is known to induceAMgene expression in tumor cells and
endothelial cells via the transcription factor, HIF-1 (19,
20). AM is known to be expressed in the human endome-
trium (12, 21), but its regulation and differential expres-
sion across the menstrual cycle remain unknown.
The purpose of this studywas to investigate the expres-
sion and regulation of AM in human endometrium. We
hypothesized that endometrial hypoxia and PG produc-
tion initiate the up-regulationof factors involved in repair.
Here,wehave demonstrated that endometrialAMmRNA
expression peaked during menstruation, with maximal
AM protein observed inM and P phase biopsies. We have
identified that progesterone withdrawal, followed by hy-
poxic conditions and PGF2 synthesis, increased endome-
trial AM expression. Hypoxia-regulated AM expression
wasmediated byHIF-1, whereas PGF2 up-regulated AM
by a HIF-1-independent pathway. Furthermore, we have
demonstrated that endometrial production of AM signif-
icantly increased vascular and lymphatic endothelial cell
proliferation and branching, suggesting it plays an impor-
tant role in endometrial repair and regeneration.
Materials and Methods
Tissue collection
Endometrial biopsies were collected with a suction curette
(Pipelle; Laboratorie CCD, Paris, France) from women with a
subjective complaint of HMB having investigation in the out-
patient setting (n 22) or undergoing hysterectomy (n 29). At
hysterectomy, a full-thickness endometrial biopsy was also col-
lected for immunohistochemical studies. Ethical approval was
obtained from the LothianResearch Ethics Committee andwrit-
ten informed consent from all participants. Women were aged
31–52 yr (median, 41; mean, 41) with regular menstrual cycles
(21–35 d) and no exogenous hormone or intrauterine device use
in the 3 months before biopsy. Women with large (3 cm) or
submucosal fibroids on ultrasound examination were excluded.
Women with confirmed endometriosis or with a history of per-
sistent premenstrual dyspareunia or infertility were excluded.
Tissue was placed in 1) RNA later, RNA stabilization solution
(AmbionLtd.,Warrington,UK); 2) neutral buffered formalin; or
3) PBS for in vitro culture and dated according to the criteria of
Noyes et al. (22). The participant’s reported last menstrual pe-
riod was recorded and serum estradiol and progesterone levels
measured at the time of biopsy (Table 1). Biopsies were consis-
TABLE 1. Classification of endometrial samples examined in this study
Histological stage
of cycle Mean age Day of cycle
Mean E2 pmol/litre
(range)
Mean P4 nmol/litre
(range)
M (n  8) 41 2–3 192.25 (55–514) 3.71 (1.24–10.59)
P (n  16) 42 6–16 441.18 (79–1105) 2.81 (0.97–7.1)
ES (n  10) 42 17–21 497.50 (289–841) 59.60 (23.2–112.91)
MS (n  11) 40 21–25 638.00 (242–1949) 64.30 (25.47–114.53)
LS (n  6) 42 22–29 318.22 (59.09–819) 8.22 (1.06–16.95)
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tent for all three criteria and classified as proliferative (P), early
secretory (ES), midsecretory (MS), late secretory (LS), or men-
strual (M) for analysis.
Immunohistochemistry
AMandCLR localizationwas studied by immunohistochem-
istry, using standard methods. Antigen retrieval was performed
bypressure cooking in boiling 0.01M citrate buffer (pH6.0), and
endogenous peroxidase activity was quenched with 10% (vol/
vol)H2O2 inmethanol. After blocking for 30min in nonimmune
goat serum, sectionswere incubatedovernight at 4Cwith1:1000
rabbit antihuman AM (Phoenix Pharmaceuticals, Karlsruhe,
Germany) or rabbit antihuman CLR, previously described in
Ref. 15. An avidin-biotin peroxidase detection system was used
(Dako Ltd., Cambridge, UK) with 3,3-diaminobenzidine. Con-
trols were incubated with isotype-matched IgG or nonimmune
serum instead of primary antibody.
CLR,CD31 (platelet endothelial cell adhesionmolecule), and
podoplanin expression was studied by triple immunofluores-
cence immunohistochemistry. Sections were prepared as above,
blocked with 20% nonimmune serum, and incubated sequen-
tiallywith rabbit anti-CLRantibody (1:3000), rabbit anti-CD31
antibody (1:1000) (Abcam, Cambridge, UK), and sheep antihu-
man podoplanin (1:500) (R&D Systems, Abingdon, UK), for
18 h at 4 C. Control sections were incubated with an equivalent
concentration of normal IgG or nonimmune serum. Detection
was performed using goat antirabbit or donkey antisheep Fab
fragment-peroxidase, as appropriate, at a dilution of 1:500
(DakoLtd.) followedby incubationwithTyr fluorescence (CLR;
green), TyrCy5 (CD31; blue), and TyrCy3 (podoplanin; red) for
10 min at a dilution of 1:50 (PerkinElmer, Wokingham, UK).
Between antibodies, sections were microwaved for 2.5 min in
0.01M citrate buffer (pH6.0). Sectionswere counterstainedwith
4,6-diamidino-2-phenylindole (Invitrogen, Carlsbad, CA) in
PBS and mounted in PermaFluor (Immunotech-Coulter, Brea,
CA) and coverslipped. Controls included replacement of the an-
tibody to CLR with an antibody that does not bind to vessels
(antihuman CD56 as the first antibody) and preimmune serum
from the same rabbit that was used to raise the anti-CLR anti-
body. Fluorescent images were visualized and photographed us-
ingaCarlZeiss (Jena,Germany) laser scanningmicroscopeMeta
LM 510.
Scoring of immunohistochemical staining
Localization and intensity of AM immunostaining was eval-
uated blindly by two independent observers using a previously
validated semiquantitative scoring system (23). Intensity anddis-
tribution of staining was rated as described previously (24). In-
tensity was graded using a three-point scale (0, no staining; 1,
mild staining; 2, strong staining). The percentage of cells stained
at eachof these intensitieswas assessed in the glandular epithelial
cells and stromal cells inboth thebasal and functional layerof the
endometrium. The surface epithelial cells and endothelial cells
were also assessed where visible. A value was derived for each of
the cellular compartments by using the sum of these percentages
after multiplication by the intensity of staining.
Cell culture
Human Ishikawa endometrial adenocarcinoma cells (Euro-
pean Collection of Cell Culture, Centre for Applied Microbiol-
ogy,Wiltshire, UK) stably expressing the EP2 receptor (EP2S) or
the FP receptor (FPS) were maintained as previously described
(25). Approximately 4  105 EP2S or FPS cells were seeded in
six-well plates. The next day, cells were washed in PBS and in-
cubated in serum-free culturemediumcontaining antibiotics and
8.4 M indomethacin for at least 16 h. Cells were treated with
vehicle, 100 nM PGE2 (EP2S cells), or 100 nM PGF2 (FPS cells)
and placed in either normoxia (21% O2, 5% CO2, 37 C) or
hypoxic conditions (0.5%O2, 5%CO2, 37 C) in a sealed cham-
ber (Coy Laboratory Products, Inc., Grass Lake, MI) for 24 h.
To examine the contribution of HIF-1, cells were pretreated
with vehicle or 1, 2, 5, or 10 nM echinomycin (an inhibitor of
HIF-1 DNA binding activity) for 1 h. Cells were then stimulated
with vehicle, 100 nM PGF2 echinomycin, or hypoxia echi-
nomycin for 8 h.
Tissue culture
Endometrial biopsies (secretory phase, n 4; P phase, n 3)
were divided into four equal explants and incubated on raised
platforms in 24-well plates, with 1 ml of serum-free RPMI 1640
medium and 8.4 M indomethacin for 16 h. One explant was
then treated with vehicle and one with 100 nM PGF2 in nor-
moxia (21% O2, 5% CO2, 37 C). The remaining two explants
were treated in the same way and placed in a sealed hypoxic
chamber (CoyLaboratoryProducts) set at 0.5%O2,5%CO2,37
C for 24 h.
Five further P biopsies were divided into eight equal-sized
explants and placed on raised platforms. All explants were
treatedwith 1Mmedroxyprogesterone acetate (MPA) for 24 h.
Explantswere then treatedwith either 1) 1MMPAplus vehicle,
2) 1 MMPA plus 8.4 M indomethacin (a COX enzyme inhib-
itor), 3) 1 M MPA and 1 M RU486 (a progesterone receptor
antagonist) plus vehicle, or 4) 1MMPAandRU486plus 8.4M
indomethacin.One platewas placed in normoxic conditions and
the other in hypoxic conditions for 48 h.
Quantitative RT-PCR (Q-RT-PCR)
Total RNA from cells and homogenized endometrial tissue
was extracted using theRNeasyMini kit (QIAGENLtd., Sussex,
UK) according to the manufacturer’s instructions. Samples were
quantified and assessed for quality as previously described (7,
26). RNA samples were reverse transcribed as described previ-
ously (26). A tube with no reverse transcriptase was included to
exclude DNA contamination. Real-time quantitative PCR was
carried out using an ABI Prism 7900 Sequence Detection System
(Applied Biosystems, Warrington, UK) as previously described
(26). Primer and probe sequences are listed inTable 2.Datawere
analyzed and processed using Sequence Detector version 2.3 (PE
Biosystems, Foster City, CA). Expression of target mRNA was
normalized to RNA loading for each sample using the 18S ri-
bosomal RNA as an internal standard.
TABLE 2. Sequences of primers and probes used for
TaqMan RT-PCR analysis
AM Forward 5-CCGACGGCCGCGTTGAC-3
Reverse 5-GACACAACTCCTCTCTCTT-3
Probe 5-FAM-CAAACTCCCTTGGCTCACC-TAMRA-3
CLR Forward 5-GGACTCAATTCAGTTGGGAGTTACTAG-3
Reverse 5-GAGCCATCCATCCCAGGTT-3
Probe 5-FAM- CCCCATTCAACAAGCAGAAGGCGTTT-
3-TAMRA
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Short hairpin RNA (shRNA) against HIF-1
Two different 19-nucleotide shRNA sequences derived from
human HIF-1mRNA (U22431; bp 1470–1489 and bp 2192–
2211) were used and termed HIF-1/shRNA1470 and HIF-1/
shRNA2192 (27, 28). In addition, control oligonucleotides (TIB
MOLBIOL)were used and termed (ShSCR). FPS cells were tran-
siently transfected with lentivirus at multiplicity of infection 10
for 24 h. Cells were incubated in serum-free medium overnight
before treatmentwith100nMPGF2orplacement in thehypoxic
chamber for 8 h. Cells were washed with PBS and harvested and
RNA or protein extracted for PCR or Western blot analysis.
Adrenomedullin enzyme immunoassay
AM concentration in conditionedmedia was measured using
a human AM (1-52) enzyme immunoassay kit from Phoenix
Peptides (Karlsruhe, Germany) according to manufacturer’s in-
structions. All samples were analyzed on the same plate. Mini-
mum detectable concentration, 0.13 ng/ml; interassay error, less
than 14%; intraassay error, less than 5%. There was 100%
cross-reactivity for rat AM (1-50) and human AM (13-52) and
mouse AM (1-50) but no reported cross-reactivity for endothe-
lin-1, amilin, CGRP, CGRP-2, -atrial natriuretic peptide, or
brain natriuretic peptide-32.
Functional assays
Human umbilical vein endothelial cells (HUVEC) (Lonza,
Wokingham,UK) andhumandermal lymphatic endothelial cells
(HDLEC) (TCS CellWorks, Buckingham, UK) were maintained
in endothelial cell growth medium, EGM-2 (Lonza) and MV2
(PromoCell, Heidelberg, Germany), respectively, with recom-
mendedgrowth supplements. Flasks formaintenanceofHDLEC
were precoated with fibronectin (1 mg/ml; Sigma, Poole, UK).
Preparation of conditioned medium
The 1  107 FPS cells were seeded in a 162-cm2 flask and
treated with vehicle or 100 nM PGF2 in 30 ml of serum-free
medium containing indomethacin for 48 h. Vehicle-treated con-
ditioned medium (control conditioned medium, CCM) or
PGF2-treated conditionedmedium (PCM)was then centrifuged
and the supernatant frozen at 20 C until use.
Proliferation assay
HUVEC and HDLEC cells were seeded in 96-well plates at a
concentration of 3 103 cells per well and starved overnight in
EBM-2 basalmedium supplementedwith 1% fetal bovine serum
and antibiotic. Cells were treated (six replicates per sample)with
vehicle, 1nMAM,CCM,PCM,or the same in thepresenceof one
of twoCLRantagonists,CGRP8–37, orAM22–52 (eachusedat10
nM) for 96 h, with reagents replenished at 48 and 72 h. Prolif-
eration was then measured with Cell Titer 96 Aqueous One so-
lution reagent (Promega, Southampton, UK) according to the
manufacturer’s instructions. Results are displayed as PCM-
treated cells divided by relative controls, i.e. CCM-treated cells.
Network assay
If stimulated, HUVEC andHDLEC cells branch toward each
other to forming capillary tubes or networks in vitro. The degree
of network formation can be assessed by measurement of the
number of branch points between the tube-like structures
formed, providing a quantification of angiogenic potential. In-
serts of 12-well 0.4 mm transwell plates (Corning Costar, Cam-
bridge,UK)were coated in80l of growth factor reducedMatri-
gel (BD Biosciences, Oxford, UK) either alone or in the presence
of 10 nM CGRP8–37 or 1 nM AM22–52. Matrigel was incubated
at 37 C for 30 min; 2.5  104 HUVEC or HDLEC cells in sus-
pension were then added to the inserts in a 500l volume of 1%
medium;1mlof controlmedium,AM,CCM,orPCMwasadded
to the bottom chamber and incubated for 16 h at 37 C.
Cells were fixed in ice-cold methanol and stained with he-
matoxylin.Networkswere photographed using anAxiovert 200
microscope (Zeiss, Welwyn Garden City, UK), and the number
of branch points was counted by an observer blinded to the
treatment of the well. As each treatment was carried out in du-
plicate, the mean branch point count was calculated after
unblinding.
Statistics
FormRNAexpression in tissue explants, cell culture, or func-
tional assays, results were expressed as fold increase, for which
relative expression of mRNA in treated samples was divided by
the relative expression in vehicle-treated samples. Data are pre-
sented as mean  SEM. Significant difference was determined
using one-way ANOVA of delta cycle threshold values, with
Tukey’s post hoc test analysis. For endometrial biopsies from
across the menstrual cycle, results were expressed as quantity
relative to a comparator, a sample of RNA from the liver. Sig-
nificant difference was determined using Kruskal-Wallis non-
parametric test with Dunn’s multiple comparison post hoc test
(Instat, GraphPad Software, Inc., San Diego, CA).
Results
AM expression across the M cycle
AM mRNA expression in homogenized endometrial
biopsies was low in samples from the P and secretory
phases of the cycle. Expression peaked at menstruation,
when AM mRNA levels were significantly higher than
during the P phase (P 0.001) (Fig. 1A). Immunostaining
for AMwas detected in a cytoplasmic location in the sur-
face epithelium (SE), glandular epithelium (GE), stromal
compartment (St), and endothelial cells (Fig. 1B). More
positive staining was observed in the functional endome-
trial layer than in cells located in the basal portion of the
endometrium (Figs. 1, B and C, i–iv). Strongest staining
was observed in the SE, and this did not vary significantly
throughout the cycle (Fig. 1C, v). In contrast, semiquan-
titative assessment of staining in the GE revealed signifi-
cantly greater staining in theMphase, comparedwithMS
endometrium, in both the functional and basal layers (P
0.05). There was also increased staining of P phase GE
cells, but this did not reach statistical significance (Fig. 1C,
i and ii). There was no significant difference in staining
scoreof the stromal cell compartment across the cycle (Fig.
1C, iii and iv). Endothelial cells from all phases stained
positively for AM (Fig. 1C, vi).
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Endometrial CLR expression
CLRmRNAwas present throughout themenstrual cycle
(Fig. 2A). Highest levels were observed in the MS phase,
when CLR expression was significantly higher than in the P
(P0.01) andLS stage (P0.05) (Fig. 2A).To characterize
the siteofCLRexpression, sectionswere stainedsequentially
with antibodies to CLR, CD31 (a pan-endothelial marker),
and podoplanin (a lymphatic endothelial marker). CLR
and CD31 were expressed in all vessels (Fig. 2, B and C).
In contrast, podoplanin was expressed in only a propor-
tion of vessels, predominantly in the basal layer of the
endometrium (Fig. 2D).This showsCLRwaspresent both
in the blood vessels (podoplanin-negative, CD31-, and
CLR-positive vessels) and lymphatics (CD31-, CLR-, and
podoplanin-positive vessels).
Regulation of endometrial AM expression
PGF2andhypoxicconditionsup-regulateAMexpression
in endometrial epithelial cells
To determine the impact of PG and hypoxia on AM ex-
pression, we first used an endometrial epithelial cell line sta-
bly transfectedwith either the PGE2 receptor (EP2S) orwith
the PGF2 receptor (FPS). Treatment of EP2S cells with 100
nMPGE2 had no significant impact onAMexpression at 8 h
(Fig. 3A) or 2, 4, 24, or 48 h (data not shown). EP2S cells
placed in hypoxic conditions (0.5% O2) displayed a signif-
icantup-regulationofAMmRNAexpression,witha50-fold
increase over cells in normoxic conditions (P 0.001) (Fig.
3A).Therewasno further increasewhencellswere cotreated
with hypoxia and 100 nM PGE2. Treatment with 100 nM
PGF2 significantly increasedAMmRNAexpression in FPS
cells, resulting in a more than 11-fold increase over vehicle-
treated cells after 8 h (P 0.001) (Fig. 3B). Hypoxic condi-
tions significantly increasedAMexpression inFPScellsmore
than 6-fold (P  0.001). Interestingly, cotreatment of FPS
cells with PGF2 and hypoxia resulted in a synergistic in-
crease in AM mRNA expression (28-fold increase over
normoxic vehicle) that was significantly greater than treat-
mentwithPGF2orhypoxiaalone (P0.05andP0.001,
respectively). Analysis of culture supernatants by ELISA re-
vealed no significant differences in AM-secreted protein levels
after24h,butasimilarpatternemerged,withincreasedsecreted
AM protein from cells treated with both PGF2 and hypoxia
compared with vehicle treatment in normoxia (Fig. 3C).
FIG. 1. AM levels in the human endometrium at different stages of the menstrual cycle. A, AM mRNA expression was determined by Q-RT-PCR,
normalized using 18S rRNA as an internal standard. B, AM protein was present in the surface epithelial (SE), glandular epithelial (GE) cells, the
stromal compartment (St), and endothelial cells (arrows) during the M and P phase. Staining was markedly decreased during the secretory phase.
Inset, Negative control. Scale bar, 100 or 50 m as marked. C, Scoring of immunohistochemical staining for AM in GE cells of the functional (F)
layer (i), GE cells in the basal (B) layer (ii), the St of the functional endometrial layer (iii), the St in the basal layer (iv), SE cells (v), and endothelial
cells in both endometrial layers (vi). My, Myometrium; KW, Kruskal Wallis statistical analysis. *, P  0.05.
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PGF2 and hypoxia up-regulate AM expression in
secretory endometrial tissue
To further investigate PGF2 and hypoxia-mediated
AM expression, we treated endometrial tissue explants
with 1) vehicle, 2) 100 nM PGF2, 3) hypoxic conditions,
or 4) PGF2 and hypoxia. P biopsies revealed no signifi-
cant differences inAMmRNAexpressionwith these treat-
ments (n  3) (Fig. 4A). In contrast, endometrial tissue
from the secretory phase did show a significant increase in
AMexpressionwhen placed in hypoxic conditions (n 4)
(4-fold, P  0.05) (Fig. 4B). In addition, there was a
nonsignificant 2-fold increase in AM expression after
treatmentwith PGF2 in normoxia. This suggests that pre-
vious exposure to progesterone is a prerequisite to enable
up-regulation of AM by PGF2 and hypoxia.
Progesterone withdrawal, in the presence of
hypoxia and PG, up-regulates AM expression in P
endometrial tissue
To examine the contribution of progesterone exposure
and withdrawal, we used an in vitro model of progester-
FIG. 2. CLR in human endometrium from across the menstrual cycle. A,
CLR mRNA expression. ns, No significant difference. *, P 0.05; **, P
0.01; ***, P 0.001. Immunolocalization of CLR (B) (green) was present
in the vasculature of the endometrium and colocalized both with
endothelial cell marker CD31 (C) (blue) and lymphatic vessel marker
podoplanin (PDPN) (D) (red). Blood vessel (BV) is negative for podoplanin,
but lymphatic vessel (LV) is positive for all three antibodies.
FIG. 3. PGF2 and hypoxia up-regulate AM expression in an
endometrial epithelial cell line. A, 100 nM PGE2 did not up-regulate
AM expression in EP2S cells after 8 h, whereas hypoxic conditions
(0.5% O2) significantly increased AM expression. B, 8-h treatment with
100 nM PGF2 or hypoxia significantly increased AM expression in FPS
cells. Cotreatment with both factors revealed a synergistic increase in
AM expression. C, Secreted AM protein levels in conditioned media
from FP cells treated with 100 nM PGF2 and/or hypoxia for 24 h. a and
b, P  0.001; c and d, P  0.05; e and f, P  0.01.
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one antagonism. P explants were treated with progester-
one followed by progesterone and mifepristone (RU486,
a progesterone receptor antagonist), to mimic progester-
one withdrawal. There was no significant difference in
endometrial AMmRNA expression in explants subjected
to progesterone withdrawal when compared with those
maintained inprogesterone.However,whenprogesterone
withdrawal was carried out in hypoxic conditions, a sig-
nificant increase in AM mRNA expression was observed
(P  0.05) (Fig. 4C). The contribution of PGs, which are
up-regulated downstream of progesterone withdrawal,
was assessed by coculture of explants with indomethacin,
a COX enzyme inhibitor. Addition of indomethacin re-
sulted in abrogation of the AM increase observed after
progesterone withdrawal in hypoxic conditions (Fig. 4C).
AM induction by hypoxia, but not by PGF2, is
dependent on HIF-1
To assess the contribution of the transcription factor
HIF-1, we treated endometrial epithelial cells with echi-
nomycin. This small molecule inhibits HIF-1 binding to
hypoxic response elements on target genes, thereby pre-
ventingHIF-1-induced transcription (29). Cotreatment of
FPS cells with 100 nM PGF2 and 1–10 nM echinomycin
had no significant effect on AM mRNA expression (Fig.
5A). In contrast, echinomycin prevented AM up-regula-
tion by hypoxia in a dose-dependent manner (Fig. 5B).
AM expression was significantly reduced in cells treated
with hypoxia and 5–10 nM echinomycin when compared
with hypoxia treatment in the absence of echinomycin.
To confirm these findings, we used two different
shRNA sequences against HIF-1 (HIF-1/Sh1470 and
HIF-1/Sh2192). HIF-1 silencing was confirmed by
Western blot analysis and TaqMan Q-RT-PCR (Supple-
mental Fig. 1, A and B, published on The Endocrine So-
ciety’s Journals Online web site at http://endo.endojour-
nals.org). Specificity of the shRNA sequences was
confirmed with measurement of Lamin A/CmRNA levels
(Supplemental Fig. 1C). HIF-1 silencing had no signifi-
cant impact on PGF2-induced AM mRNA expression
(Fig. 5C). However, hypoxic induction of AMwas signif-
icantly lower in those cells in which HIF-1was silenced,
when compared with untransfected cells or cells trans-
fected with HIF-1/ShSCR (P  0.05) (Fig. 5D).
Endometrial AM regulates endothelial cell function
To investigate downstream effects of endometrial
AM production, we treated endothelial cells (HUVEC/
HDLEC) for 96 h with 1 nM AM, PCM, and the same
reagents in the presence of twoAMreceptor antagonists
CGRP8–37 (10 nM) and AM22–52 (10 nM). Endothelial
cell proliferation and network formation were assessed
in both cell types and displayed in Fig. 6 as fold increase
over controls (vehicle treatment or cells treated with
control conditioned medium).
Treatment ofHUVEC cells withAMor PCM induced
1.69 (0.28)- and 2.1 (0.1)-fold increases in HUVEC
proliferation, respectively. These effects were inhibited
by the AMantagonists (Fig. 6A). Similarly, treatment of
lymphatic endothelial cells (HDLEC) with AM and
FIG. 4. Hypoxia and PGF2 significantly increase AM expression in
endometrial tissue previously exposed to progesterone. A, P phase
explants of endometrium exposed to vehicle, 100 nM PGF2, 0.5% O2
or both for 24 h (n  3). B, Identical treatment of secretory phase
biopsies (n  4). C, P phase explants (n  5) were pretreated with1 M
MPA and then 1) maintained in 1 M MPA (P), 2) cotreated with 1 M
MPA and 1 M RU486, a progesterone receptor antagonist (P 
RU486), or 3) cotreated with 1 M MPA, 1 M RU486, and 8.4 M
indomethacin, a COX enzyme inhibitor (P  RU486  Indo). Identical
treatments were incubated in either normoxia (21% O2) or hypoxia
(0.5% O2). ns, Nonsignificant. *, P  0.05.
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PCM induced small but significant increases in HDLEC
proliferation, which were inhibited by chemical antag-
onists (Fig. 6B).
To further investigate the effect of PGF2-mediated en-
dometrialAMexpressiononendothelial cell function,net-
work formation of endothelial cells was studied in the
presence of AM and PCM. AM induced a 1.56 (0.19)-
fold increase in the number of networks formed by
HUVEC, whereas PCM caused a 1.84 (0.05)-fold in-
crease. These effects were significantly inhibited by the
AM receptor antagonists (P  0.05) (Fig. 6C). A similar
effect of AM and conditioned media on network forma-
tion was observed in HDLEC. In this case AM and PCM
induced 1.25 (0.05)- and 1.75 (0.23)-fold increases in
network formation, respectively, whichwere again signif-
icantly inhibited by the antagonists (P  0.05) (Fig. 6D).
Discussion
This studydemonstrates significant, novel advances in our
understanding of human endometrial repair. Firstly, we
show significant menstrual up-regulation of
AMmRNAexpression.Protein levels arealso
highest during theMandP stages, a temporal
pattern consistent with a role in repair and
regeneration. Secondly, we demonstrate that
endometrial AM is regulated by two distinct
mechanisms: a HIF-1-mediated hypoxic in-
duction and a novel, HIF-1 independent,
PGF2 pathway. Both these pathways are in-
ducedbyprogesteronewithdrawal during the
LSphase.Finally,weshowthatAMproduced
by endometrial cells has a significant impact
on both vascular and lymphatic endothelial
cell function in vitro. These data suggest that
AM may have an active role in endometrial
repair.
The expression of AM in the human en-
dometrium has been studied previously (12,
21, 30, 31), but we present the first detailed
analysis of endometrial AM expression at
well-defined stages of the menstrual cycle.
We show, for the first time, that AMmRNA
and protein are high during menstruation,
when repair is initiated. Immunolocaliza-
tion revealed AM in the SE, GE, St, and en-
dothelial cells, in agreement with previous
in situ hybridization studies (30). We ac-
knowledge that our study population had a
subjective complaint of HMB. Previous
studies have shown that 64% of women
with subjective heavy loss actually had a
normal objective measurement (32). However, further
studies are required to determine whether blood loss has
an impact on endometrial AM expression. Maximal AM
localization was in the functional endometrial layer. A
recent study comparing the functional and basal endome-
trial layers at menstruation found that genes associated
with extracellular matrix biosynthesis were greatest in the
lysed functional layer (33), suggesting fragments of this
layerhaveanactive role in endometrial repair.Our finding
of high levels of AM protein in P endometrium is consis-
tent with findings in the mouse and rat uterus (34, 35).
However, our study also revealed high levels of AM pro-
tein during the M phase, when estradiol levels are low.
This suggests an additional estradiol independent mech-
anism of AM up-regulation. This is consistent with ob-
servations in the mouse model of simulated menstruation
(2). The absence of estradiol support in ovariectomized
mice, with additional removal of extraovarian estrogenic
influence using an aromatase inhibitor, had no signifi-
cant impact on the rate of endometrial repair. Notwith-
standing the limitations of this mouse model, these data
FIG. 5. Inhibition of HIF-1 prevents hypoxia-mediated AM expression but not PGF2-
induced expression. A, Endometrial epithelial cells (FPS) treated with 100 nM PGF2 and
echinomycin (EC) (a pharmacological inhibitor of HIF-1 binding) showed no significant
difference in AM expression (n  3). B, Cells treated with 5–10 nM echinomycin in
hypoxic conditions significantly abrogated the hypoxic induction of AM expression (n 
3). C, Silencing of HIF-1 with two short hairpin sequences against HIF-1 (Sh1470 and
Sh2192) had no significant effect on PGF2-mediated AM expression. D, Cells
transfected with shRNA against HIF-1 had a significantly abrogated response to
hypoxic stimulation, with low levels of AM expression compared with untransfected cells
or those transfected with a scrambled sequence (ShSCR). a and b, P  0.001; b-c, P 
0.01; b-d, P  0.05. ns, Nonsignificant; NV, normoxia and vehicle.
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support our findings in the human endometrium, sug-
gesting factors with a role in initial repair are not reliant
upon estrogen for their expression.
Nikitenko et al. (30) previously identified the endome-
trial expression of CLR by RT-PCR but did not assess its
level of expressionacross the cycle.WeobservedhighCLR
expression during the ES phase, with low levels during the
M and P phases. This inversely correlates to the pattern of
endometrial AM expression. Internalization and desensi-
tization of the endogenousCLR in endothelial cells occurs
after exposure toAM(15), suggesting the functionofCLR
is tightly regulated by its ligand. A similar pattern of re-
duced CLR expression was seen in the mouse model of
sepsis, where AM expression is markedly up-regulated
(36). Further studies of this receptor, in particular inves-
tigation of the endometrial expression of the receptor ac-
tivating binding proteins, are required to confirm its func-
tional role and affect on AM responsiveness.
Our finding thatCLRprotein is localized to endothelial
cells of blood vessels in the human endometrium is con-
sistent with previous studies (30, 37, 38). In addition, we
have demonstratedCLR localization in the lymphatic vas-
culature. Nikitenko et al. (15) have previously shown that
treatment of primary endometrial endothelial cells with
a synthetic AM peptide increased their
growth in vitro. Our study supports and ex-
tends this work.We have demonstrated sig-
nificantly increased proliferation and net-
work formation of macrovascular and
lymphatic endothelial cells treatedwithAM
produced endogenously by endometrial
cells. Confirmation of these findings in mi-
crovascular endothelial cells, as found in the
human endometrium, is necessary. These
processes are essential for the repair of dam-
aged blood vessels atmenstruation (39, 40).
Endometrial lymphangiogenesis has re-
cently emerged as an important process in
the normal menstrual cycle (40). The lym-
phatics play a vital role in tissue fluid bal-
ance and immune surveillance. A study of
endometrial lymphatic vessels identified
small sparsely distributed vessels in the
functional layer, with larger lymphatic ves-
sels in the basal layer, often closely associ-
ated with spiral arterioles (41). This associ-
ation may indicate that the lymphatics have
a regulatory role in spiral arteriole function.
Importantly, AM has been shown to pro-
mote the proliferation, migration, and net-
work formation of cultured lymphatic mi-
crovascular endothelial cells and reduces
secondary lymphoedema in mice with tail
injury (42).Our results suggest that endometrial epithelial
cell AM production increases blood and lymphatic endo-
thelial cell proliferation and network formation. An al-
ternative explanation is that PGF2 has an autocrine effect
on endothelial cell AM production to increase their pro-
liferation (15). Either way, these data provide further sup-
port for a functional role for AM in human endometrial
repair.
The regulation of endometrial AM expression has not
previously been defined.Here,we have demonstrated that
endometrial cellAMexpression is inducedbyhypoxia and
by a novel PGF2-mediated pathway. As our immunohis-
tochemistry data showed strong staining in epithelial cells,
we used an endometrial epithelial cell line stably trans-
fected with either the PGE2 receptor (EP2) or the PGF2
receptor (FP). These cell lines were used because primary
endometrial epithelial cells have a limited capacity for pro-
liferation in vitro but do express PG receptors in vivo (43,
44).Wehave shown that PGF2 significantly up-regulated
endometrial AM expression, whereas PGE2 had no such
effect. Inflammatory cytokines, such as TNF- and IL-1,
have previously been shown to regulate AM expression
(45), butour report is the first onAMregulationbyPGF2.
FIG. 6. PGF2-induced AM secretion up-regulates proliferation and network formation
in human vascular endothelial cells and in HDLEC. Proliferation in HUVEC cells (A) and
HDLEC cells (B) in response to AM, AM in the presence of CLR antagonists (CGRP8–37
and AM22–52), PGF2 treated conditioned medium (PCM), or PCM in the presence of
CLR antagonists (n  9–10). Network formation in HUVEC cells (C) and HDLEC cells (D)
in response to AM, PCM, and AM or PCM in the presence of CLR antagonists (CGRP8–37
and AM22–52) (n  4–5). a and b, P  0.05.
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PGF2 is emergingas apotential keyplayer in the initiation
of endometrial repair factor expression. We have previ-
ously demonstrated PGF2 induction of a host of endo-
metrial angiogenic factors, including vascular endothelial
growth factor, fibroblast growth factor-2, and IL-8 (46–
48). In addition to this novel pathway of AM regulation,
we also confirmed hypoxic induction of endometrial AM
expression, an effect previously demonstrated in other cell
types (49, 50).
To further delineate the mechanisms controlling endo-
metrial AM expression, we assessed the contribution of
HIF-1. HIF-1 is a transcription factor composed of two
subunits: the oxygen-destructible HIF-1 subunit and the
constitutively expressed HIF-1. As a heterodimer, it
binds to hypoxic response elements on target genes, which
include angiogenic and mitogenic factors, such as AM,
vascular endothelial growth factor, connective tissue
growth factor, and IL-8 (51–54). In addition to its stabi-
lization in hypoxic conditions, there is evidence that in-
flammatory mediators, e.g. PG, can induce HIF-1 in nor-
moxia (7, 55).Therefore,we examined the contributionof
HIF-1 to both hypoxia and PGF2-mediated up-regula-
tion of AM in our endometrial cell line. Both pharmaco-
logical inhibition of HIF-1 binding and silencing of
HIF-1 with shRNA elicited a significant abrogation of
hypoxia-induced AM up-regulation. These results concur
with findings in cardiomyocytes and human tumor cell
lines (53, 56). In contrast, we found that inhibition of
HIF-1 had no impact on the ability of PGF2 to increase
endometrial cell AM expression. Therefore, we propose
that two independent pathways are active in the endome-
trium to regulate AM expression: a HIF-1-dependent hy-
poxic pathway and a novel PGF2 pathway that is not
reliant on HIF-1 activity.
Interestingly, when examining the effect of PGF2 and
hypoxic treatment of primary endometrial explants, in-
creases in AM expression were only observed in explants
taken during the secretory phase of the cycle. This sug-
gested that previous progesterone exposure is necessary
for endometrial AM up-regulation. To test this hypothe-
sis, we subjected P endometrium to a previously described
ex vivomodel of progesterone antagonism (57), to mimic
progesterone withdrawal in the LS phase. When explants
were cotreated with progesterone and a progesterone re-
ceptor antagonist, therewas no significant increase in AM
expression over explants maintained in progesterone
alone. However, when progesterone is withdrawn in vivo
the spiral arterioles constrict, resulting in a hypoxic epi-
sode that was not accounted for in our model. Therefore,
we treated explants from the same biopsies in an identical
manner but placed them in a hypoxic chamber. Proges-
terone withdrawal in hypoxic conditions significantly in-
creased endometrial AM expressionwhen comparedwith
explants treated in normoxic conditions. Addition of the
COX inhibitor indomethacin abrogated this AM up-reg-
ulation. These data suggest that progesterone withdrawal
up-regulates endometrial AM expression but only in the
presence of hypoxia and PGs. Although the contribution
of hypoxia to the initiation of menstruation is currently
controversial (58), our results suggest that endometrial
hypoxia has an important role in the initiation of repair.
In summary, our work describes the expression of AM
and its receptor in human endometrium across the men-
strual cycle.Our study identified apeak inAMmRNAand
protein expression at menstruation, coinciding with the
initiation of endometrial repair.We provide evidence that
AM produced endogenously by endometrial cells is func-
tionally active, in that it can stimulate proliferation and
capillary branching of vascular and lymphatic endothelial
cells. In addition, we demonstrate regulation of endome-
trial AM expression via two separate pathways: a novel
PGF2pathwayandhypoxic inductionviaHIF-1.Wepro-
pose that these pathways are activated in the endometrium
after progesterone withdrawal in the LS phase, to up-reg-
ulateAMfor endometrial repair.AberrantAMexpression
and regulation in the endometrium may contribute to
defective repair and subsequent clinical presentations of
prolonged bleeding or HMB. AM expression in women
with objective measurement of their menstrual loss re-
mains to be determined. Further work in this area may
aid development of effective medical treatments for this
common complaint.
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